SNSS - Sunesis Pharmaceuticals, Inc.
| Previous Close | 1.2100 |
| Open | 1.1800 |
| Bid | 1.1100 x 800 |
| Ask | 1.1700 x 3000 |
| Day's Range | 1.1100 - 1.2499 |
| 52 Week Range | 0.2000 - 2.9600 |
| Volume | 789,210 |
| Avg. Volume | 963,141 |
| Market Cap | 77.715M |
| Beta (3Y Monthly) | 4.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7480 |
| Earnings Date | Mar 7, 2018 - Mar 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.83 |
- ACCESSWIRE•15 days ago
Four Healthcare Stocks Heating Up on Thursday
This predicted growth is an indicator that more people will soon need access to quality medical care and the healthcare sector must be aptly prepared. As the healthcare sector continues to progress into the future, investors interested in potentially lucrative opportunities could benefit from focusing on this sector. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Shineco Inc (TYHT), Tonix Pharmaceuticals Holding Corp (TNXP), and Sunesis Pharmaceuticals Inc (SNSS) are 4 healthcare companies worth keeping on your radar.
- GlobeNewswire•17 days ago
Sunesis Pharmaceuticals to Present at 18th Annual Needham & Company Healthcare Conference
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the Needham & Company 18th Annual Healthcare Conference on Wednesday, April 10, 2019 at 2:10 PM Eastern Time at the Westin Grand Central Hotel in New York City. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, with an emphasis on its oral non-covalent BTK inhibitor vecabrutinib.
- Zacks•22 days ago
The Zacks Analyst Blog Highlights: Roche, Celgene, Johnson and Johnson, Bayer and Sunesis Pharmaceuticals
The Zacks Analyst Blog Highlights: Roche, Celgene, Johnson and Johnson, Bayer and Sunesis Pharmaceuticals
- Zacks•23 days ago
5 Cancer-Fighting Stocks to Boost Portfolio Gains
It would pay to invest in these companies which offer current franchises or prospective treatments for the most dreaded of diseases.
- ACCESSWIRE•28 days ago
Edison Issues Outlook on Sunesis Pharmaceuticals (SNSS)
LONDON, UK / ACCESSWIRE / March 22, 2019 / Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) is currently in the dose-escalation portion of the Phase Ib/II study of its BTK inhibitor vecabrutinib, and the first ...
- Zacks•last month
Will Sunesis Pharmaceuticals Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Sunesis Pharmaceuticals.
- Thomson Reuters StreetEvents•last month
Edited Transcript of SNSS earnings conference call or presentation 7-Mar-19 9:30pm GMT
Q4 2018 Sunesis Pharmaceuticals Inc Earnings Call
- GlobeNewswire•last month
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., March 07, 2019 -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the fourth quarter and year ended December 31,.
- GlobeNewswire•2 months ago
Sunesis Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., March 04, 2019 -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will participate in three upcoming investor.
- Zacks•2 months ago
Puma Biotech (PBYI) Q4 Loss Narrows, Nerlynx Pulls Stock Up
Puma Biotech (PBYI) betters loss estimates in Q4 and also rides high on revenue beat. Nerlynx impresses with strong sequential and year-over-year growth.
- GlobeNewswire•2 months ago
Sunesis Pharmaceuticals to Host Conference Call on March 7th to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that it will host a conference call on Thursday, March 7th, 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year ended December 31, 2018. To access the live audio webcast, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://ir.sunesis.com. The webcast will be recorded and available for replay on the company's website for two weeks.
- Zacks•2 months ago
Agios (AGIO) Q4 Earnings Beat, Tibsovo Sales Push Up Stock
Agios' (AGIO) loss tops estimates in Q4. Its precision medicine Tibsovo receives the FDA nod and leads to significant year-over-year revenue growth.
- Zacks•2 months ago
Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates
Acorda (ACOR) rides high on earnings and revenue beat in Q4. The company plans the US launch of Inbrija in first-quarter 2019.
- Benzinga•3 months ago
The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 17) Avenue Therapeutics Inc (NASDAQ: ATXI ) BioSpecifics ...
- GlobeNewswire•3 months ago
Sunesis Announces Pricing of $20 Million Offering of Securities
Sunesis Pharmaceuticals, Inc. (SNSS) today announced the pricing of underwritten public offerings of (i) 23,000,000 shares of its common stock and (ii) 17,000 shares of its non-voting Series E Convertible Preferred Stock (“Series E Stock”). The public offering price of each share of common stock is $0.50 and the public offering price of each share of Series E Stock, convertible into 1,000 shares of common stock, is $500. Sunesis has granted the underwriters a 30 day option to purchase up to an additional 3,450,000 shares of common stock to cover over-allotments, if any.
- GlobeNewswire•3 months ago
Sunesis Announces Proposed Public Offering of Common Stock and Preferred Stock
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series E Convertible Preferred Stock in underwritten public offerings. There can be no assurance as to whether or when the proposed offerings may be completed, or as to the actual size or terms of the offerings. Sunesis also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering to cover over-allotments, if any. Sunesis anticipates using the net proceeds from the proposed offerings to fund ongoing development of vecabrutinib, ongoing research and development, debt amortization, and general corporate purposes.
- GlobeNewswire•4 months ago
Sunesis Pharmaceuticals Announces Advancement into 100mg Cohort of Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that the Company has opened the 100 mg cohort in the Phase 1b/2 trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. “Thus far, we have seen an encouraging safety profile, evidence of pharmacodynamic activity in CLL and other B cell cancer patients both with and without BTK C481 mutations, and some improvements in clinical symptoms. Vecabrutinib (SNS-062) is a selective, oral, reversible, non-covalent inhibitor of Bruton's tyrosine kinase (BTK).
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of SNSS earnings conference call or presentation 5-Nov-18 9:30pm GMT
Q3 2018 Sunesis Pharmaceuticals Inc Earnings Call
- Benzinga•5 months ago
The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 3) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...
- GlobeNewswire•5 months ago
Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at ASH Annual Meeting
Sunesis Pharmaceuticals, Inc. (SNSS) today announced the presentation of results from the Company’s Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. The results will be presented today, December 2, from 6:00-8:00 p.m. PT in a poster session titled “CLL: Therapy, excluding Transplantation: Poster II” at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, California. “To date, vecabrutinib has demonstrated both an encouraging safety profile and evidence of pharmacodynamic activity in CLL and other B cell cancer patients both with and without the BTK C481 mutation,” said Dayton Misfeldt, Sunesis interim Chief Executive Officer.
- Zacks•5 months ago
Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals
Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals
- Zacks•5 months ago
5 Top-Ranked Rising P/E Stocks to Lure Investors
Inside the top-ranked stocks that have been exhibiting rising P/E ratios.
- GlobeNewswire•5 months ago
Sunesis Pharmaceuticals to Provide Program Update for Non-Covalent BTK-Inhibitor Vecabrutinib at Analyst & Investor Event during ASH 2018
Sunesis Pharmaceuticals, Inc. (SNSS) today announced it will provide a program update for vecabrutinib, the Company’s oral, reversible, non-covalent, BTK inhibitor which is currently being evaluated in an ongoing Phase 1b/2 clinical trial in adults with relapsed chronic lymphocytic leukemia (CLL) and other B-cell malignancies. Sunesis’ executive management team will present an update on vecabrutinib from the ongoing Phase 1b/2 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of vecabrutinib in B-lymphoid malignancy patients with prior BTK therapy. The Phase 1b/2 trial is an open-label, sequential-group study that is enrolling patients across eight leading sites in the United States.
- GlobeNewswire•5 months ago
Sunesis Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference
Sunesis Pharmaceuticals, Inc. (SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the 30th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018 at 7:50 A.M. Eastern Time at the Lotte New York Palace Hotel in New York City. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, with an emphasis on its oral non-covalent BTK inhibitor vecabrutinib.
- GlobeNewswire•5 months ago
Report: Developing Opportunities within NeuroMetrix, Sunesis Pharmaceuticals, Siga Technologies, NexPoint Residential Trust, Frequency Electronics, and Horizon Technology Finance — Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
